LianBio a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, announced topline results from the Phase III LIBRA clinical trial… read more.
A new compound developed at the University of Illinois Chicago potentially could offer an alternative to injections for the millions of people who suffer from an eye condition… read more.
Novartis announced that it has completed its divestment of ‘front of eye’ ophthalmology assets to Bausch + Lomb, a global eye health company, in a transaction valued up… read more.
The FDA has issued a complete response letter (CRL) regarding the supplemental Biologics License Application (sBLA) for long-acting C5 complement inhibitor Ultomiris (ravulizumab-cwvz) for the treatment of adult… read more.
New research from the University of Gothenburg has found that preterm babies given a supplement with a combination of omega-3 and omega-6 fatty acids have better visual function… read more.
Less than a third of children have gotten their vision checked in the past year at their regular primary care clinic, a new study finds. Rates of eyesight… read more.
Losing the ability to see clearly, and losing the ability to think or remember clearly, are two of the most dreaded, and preventable, health issues associated with getting… read more.
A new study suggests that eye drops developed by Columbia University researchers could be a more effective–and comfortable–therapy for a common eye disease currently treated with injections into the eye…. read more.
In a study by a research group at Baylor College of Medicine, oral administration of a commercially available probiotic bacterial strain was found to improve dry eye disease… read more.
The Japan Pharmaceutical and Medical Devices Agency (PMDA) has approved Novartis’ Luxturna (voretigene neparvovec) for the treatment of inherited retinal dystrophies (IRDs) caused by biallelic RPE65 mutations. The… read more.
Novartis announced that it has signed an agreement to divest ‘front of eye’ ophthalmology assets to Bausch + Lomb, a global eye health company, in a transaction valued… read more.
UCB announced Rystiggo (rozanolixizumab-noli) has been approved by the FDA for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) or anti-muscle-specific… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
